Overview
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Status:
Completed
Completed
Trial end date:
2001-10-30
2001-10-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory or relapsed acute leukemia, chronic myelogenous leukemia in blast phase, or myelodysplastic syndrome.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
M.D. Anderson Cancer CenterCollaborator:
National Cancer Institute (NCI)Treatments:
Dolastatin 10
Criteria
DISEASE CHARACTERISTICS: Histologically diagnosed chronic myelogenous leukemia in blasticphase, refractory or relapsed acute leukemia, or myelodysplastic syndromes (refractory
anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic
leukemia)
PATIENT CHARACTERISTICS: Age: Not specified Performance status: 0-2 Life expectancy: Not
specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL SGPT no
greater than 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance greater than 60 mL/min Other: Not pregnant or nursing Fertile patients
must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since prior chemotherapy and recovered (unless evidence of rapid disease progression)
Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified